Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Bio-Techne CorporationNASDAQ: TECH
Cash & Equivalents · Q1 FY2027 · quarter ended Sep 2026
Cash & equivalents rises 141.5% from a year ago
Cash & equivalents stood at $350.04M at the end of Q1 FY2027, up 141.5% from a year earlier and up 32.2% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Cash & equivalents amounted to 13.3% of total assets at the end of Q1 FY2027, up 7.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +141.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 264.71M USD
- Year-over-year change
- +63.2%
- 4-year CAGR
- +11.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 264.71M | +63.2% |
| FY2025 | 2025-06-30 | 162.19M | +6.8% |
| FY2024 | 2024-06-30 | 151.79M | -15.9% |
| FY2023 | 2023-06-30 | 180.57M | +4.6% |
| FY2022 | 2022-06-30 | 172.57M | — |
Cash & Equivalents vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's Sep 2026 cash & equivalents of $350.04M is the 8th highest of the 11 companies compared; the peer median is $647.34M.
- Its year-over-year change of +141.5% is the 3rd highest of 10, against a peer median of +21.7%.
- Cash & equivalents amounts to 13.3% of total assets for TECH, versus a peer median of 10.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.68B | +271.9% | -8.4% | 6.1% | |
| Sep 2026 | $5.46B | +175.5% | +4.9% | 4.8% | |
| Jul 2026 | $1.76B | +14.5% | +19.3% | 12.6% | |
| Jul 2026 | $1.02B | +3.1% | +26.5% | 8.5% | |
| Jun 2026 | $768.5M | +4.7% | +4.7% | 13.0% | |
| Sep 2026 | $526.19M | +21.7% | +29.2% | 49.5% | |
| Jun 2026 | $517M | +40.0% | +7.0% | 5.0% | |
| Sep 2026 | $350.04M | +141.5% | +13.6% | 13.3% | |
| Jun 2026 | $184.9M | +101.0% | -22.6% | 3.1% | |
ALMRAlamar Biosciences, Inc. | Jun 2026 | $132.97M | — | — | 34.0% |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Peer median (excluding TECH) | $647.34M | +21.7% | +4.9% | 10.5% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 172.57M | 180.57M | 151.79M | 162.19M | 264.71M |
| Short-term Investments | 74.46M | 23.74M | 1.07M | 0 | 0 |
| Net Receivables | 194.55M | 218.47M | 241.39M | 206.88M | 220.5M |
| Inventory | 141.12M | 171.64M | 179.73M | 189.45M | 195.74M |
| Other Current Assets | 22.86M | 27.07M | 43.43M | 49.79M | 63.45M |
| Total Current Assets | 605.56M | 621.48M | 617.42M | 608.3M | 744.4M |
| Property, Plant & Equipment (Net) | 288.8M | 324.53M | 342.44M | 319.12M | 299.17M |
| Goodwill | 822.1M | 872.74M | 972.66M | 980.94M | 975.36M |
| Intangible Assets | 531.52M | 534.65M | 507.08M | 365.6M | 303.47M |
| Long-term Investments | 0 | 255.86M | 242.34M | 250.98M | 253.39M |
| Tax Assets | 0 | 0 | 0 | 10.31M | 92.27M |
| Other Non-current Assets | 46.83M | 29.45M | 21.93M | 22.63M | 10.95M |
| Total Non-current Assets | 1.69B | 2.02B | 2.09B | 1.95B | 1.93B |
| Total Assets | 2.29B | 2.64B | 2.7B | 2.56B | 2.68B |
| Account Payables | 33.87M | 25.68M | 37.97M | 25.31M | 26.7M |
| Short-term Debt | 12.5M | 0 | 0 | 0 | 14.94M |
| Tax Payables | 13.24M | 12.02M | 3.71M | 10.77M | 0 |
| Deferred Revenue | 23.41M | 23.07M | 27.93M | 32.57M | 36.07M |
| Other Current Liabilities | 1.24M | 1.41M | 2.15M | 1.65M | 24.48M |
| Total Current Liabilities | 176.02M | 128.51M | 159.38M | 175.85M | 163.7M |
| Long-term Debt | 243.41M | 350M | 319M | 346M | 200M |
| Deferred Tax Liabilities | 98.99M | 88.98M | 55.86M | 6.17M | 111.57M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 2.33M |
| Other Non-current Liabilities | 17.24M | 10.92M | 13.16M | 27.08M | 19.02M |
| Total Non-current Liabilities | 417.78M | 543.67M | 475.64M | 463.21M | 407.07M |
| Total Liabilities | 593.79M | 672.18M | 635.02M | 639.06M | 570.77M |
| Common Stock | 1.57M | 1.58M | 1.58M | 1.55M | 1.56M |
| Retained Earnings | 1.12B | 1.31B | 1.33B | 1.07B | 1.14B |
| Accumulated OCI | (75.2M) | (66.06M) | (78.32M) | (59.88M) | (70.58M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (759K) | 0 | 0 | 0 | 0 |
| Total Equity | 1.7B | 1.97B | 2.07B | 1.92B | 2.11B |
| Total Debt | 325.97M | 454.97M | 419.54M | 444.06M | 289.09M |
| Net Debt | 153.4M | 274.39M | 267.75M | 281.87M | 24.38M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.